Etzer Darout
Stock Analyst at Barclays
(4.62)
# 215
Out of 5,149 analysts
166
Total ratings
55.15%
Success rate
28.85%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Etzer Darout
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CCCC C4 Therapeutics | Maintains: Overweight | $5 → $7 | $2.95 | +137.29% | 7 | Feb 27, 2026 | |
| JAZZ Jazz Pharmaceuticals | Initiates: Overweight | $224 | $186.67 | +20.00% | 1 | Feb 27, 2026 | |
| XNCR Xencor | Maintains: Overweight | $26 → $27 | $12.02 | +124.63% | 9 | Feb 26, 2026 | |
| PTGX Protagonist Therapeutics | Maintains: Overweight | $108 → $113 | $91.30 | +23.77% | 6 | Feb 26, 2026 | |
| VIR Vir Biotechnology | Maintains: Overweight | $26 → $30 | $8.91 | +236.70% | 1 | Feb 25, 2026 | |
| IOVA Iovance Biotherapeutics | Maintains: Overweight | $10 → $11 | $3.75 | +193.72% | 3 | Feb 25, 2026 | |
| INCY Incyte | Maintains: Overweight | $116 → $117 | $98.07 | +19.30% | 3 | Feb 18, 2026 | |
| EXEL Exelixis | Maintains: Equal-Weight | $41 → $44 | $40.74 | +8.00% | 6 | Feb 4, 2026 | |
| CTMX CytomX Therapeutics | Maintains: Overweight | $8 → $10 | $4.81 | +107.90% | 14 | Feb 4, 2026 | |
| KYMR Kymera Therapeutics | Maintains: Overweight | $119 → $133 | $86.35 | +54.02% | 5 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $58 | $58.01 | -0.02% | 4 | Jan 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $28 | $17.53 | +59.73% | 2 | Jan 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $55 → $78 | $52.83 | +47.64% | 4 | Jan 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $52 | $44.31 | +17.36% | 8 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $48 → $29 | $13.44 | +115.77% | 3 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $21 → $24 | $28.94 | -17.07% | 3 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $18 | $13.36 | +34.73% | 7 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $16 → $18 | $15.11 | +19.13% | 3 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 → $56 | $41.51 | +34.91% | 11 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 → $35 | $21.40 | +63.55% | 1 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $28 | $8.50 | +229.41% | 1 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $61 | $3.94 | +1,448.22% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $48 | $32.81 | +46.30% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $125 | $51.88 | +140.94% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $142 | $111.10 | +27.81% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $3 | $1.89 | +58.73% | 10 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $13 | $6.09 | +113.46% | 4 | Sep 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $130 → $143 | $100.76 | +41.92% | 4 | Mar 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $22 → $3 | $4.89 | -38.65% | 3 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $15.81 | +121.38% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $63 | $1.33 | +4,636.84% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $28 → $27 | $1.67 | +1,516.77% | 7 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $132 → $134 | $100.22 | +33.71% | 6 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 → $48 | $27.66 | +73.54% | 3 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $118 → $120 | $164.18 | -26.91% | 3 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $7 → $6 | $1.37 | +337.96% | 7 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $82 | $201.76 | -59.36% | 4 | Apr 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $19 | $5.52 | +244.20% | 2 | Apr 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $170 | $318.65 | -46.65% | 2 | Feb 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $27 → $38 | $87.80 | -56.72% | 2 | Sep 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $52 | $3.04 | +1,610.53% | 1 | Mar 28, 2018 |
C4 Therapeutics
Feb 27, 2026
Maintains: Overweight
Price Target: $5 → $7
Current: $2.95
Upside: +137.29%
Jazz Pharmaceuticals
Feb 27, 2026
Initiates: Overweight
Price Target: $224
Current: $186.67
Upside: +20.00%
Xencor
Feb 26, 2026
Maintains: Overweight
Price Target: $26 → $27
Current: $12.02
Upside: +124.63%
Protagonist Therapeutics
Feb 26, 2026
Maintains: Overweight
Price Target: $108 → $113
Current: $91.30
Upside: +23.77%
Vir Biotechnology
Feb 25, 2026
Maintains: Overweight
Price Target: $26 → $30
Current: $8.91
Upside: +236.70%
Iovance Biotherapeutics
Feb 25, 2026
Maintains: Overweight
Price Target: $10 → $11
Current: $3.75
Upside: +193.72%
Incyte
Feb 18, 2026
Maintains: Overweight
Price Target: $116 → $117
Current: $98.07
Upside: +19.30%
Exelixis
Feb 4, 2026
Maintains: Equal-Weight
Price Target: $41 → $44
Current: $40.74
Upside: +8.00%
CytomX Therapeutics
Feb 4, 2026
Maintains: Overweight
Price Target: $8 → $10
Current: $4.81
Upside: +107.90%
Kymera Therapeutics
Jan 28, 2026
Maintains: Overweight
Price Target: $119 → $133
Current: $86.35
Upside: +54.02%
Jan 21, 2026
Downgrades: Equal-Weight
Price Target: $58
Current: $58.01
Upside: -0.02%
Jan 21, 2026
Maintains: Overweight
Price Target: $16 → $28
Current: $17.53
Upside: +59.73%
Jan 20, 2026
Maintains: Overweight
Price Target: $55 → $78
Current: $52.83
Upside: +47.64%
Dec 17, 2025
Maintains: Overweight
Price Target: $45 → $52
Current: $44.31
Upside: +17.36%
Dec 17, 2025
Maintains: Overweight
Price Target: $48 → $29
Current: $13.44
Upside: +115.77%
Dec 17, 2025
Maintains: Underweight
Price Target: $21 → $24
Current: $28.94
Upside: -17.07%
Dec 17, 2025
Maintains: Overweight
Price Target: $16 → $18
Current: $13.36
Upside: +34.73%
Dec 17, 2025
Upgrades: Equal-Weight
Price Target: $16 → $18
Current: $15.11
Upside: +19.13%
Dec 9, 2025
Maintains: Overweight
Price Target: $36 → $56
Current: $41.51
Upside: +34.91%
Nov 24, 2025
Maintains: Overweight
Price Target: $22 → $35
Current: $21.40
Upside: +63.55%
Nov 24, 2025
Maintains: Overweight
Price Target: $11 → $28
Current: $8.50
Upside: +229.41%
Oct 13, 2025
Initiates: Overweight
Price Target: $61
Current: $3.94
Upside: +1,448.22%
Oct 13, 2025
Initiates: Overweight
Price Target: $48
Current: $32.81
Upside: +46.30%
Oct 13, 2025
Initiates: Overweight
Price Target: $125
Current: $51.88
Upside: +140.94%
Oct 13, 2025
Initiates: Overweight
Price Target: $142
Current: $111.10
Upside: +27.81%
Sep 17, 2025
Assumes: Overweight
Price Target: $3
Current: $1.89
Upside: +58.73%
Sep 2, 2025
Maintains: Buy
Price Target: $9 → $13
Current: $6.09
Upside: +113.46%
Mar 11, 2025
Maintains: Outperform
Price Target: $130 → $143
Current: $100.76
Upside: +41.92%
Feb 11, 2025
Downgrades: Market Perform
Price Target: $22 → $3
Current: $4.89
Upside: -38.65%
Dec 6, 2024
Initiates: Outperform
Price Target: $35
Current: $15.81
Upside: +121.38%
Dec 6, 2024
Initiates: Outperform
Price Target: $63
Current: $1.33
Upside: +4,636.84%
Nov 14, 2024
Maintains: Outperform
Price Target: $28 → $27
Current: $1.67
Upside: +1,516.77%
Nov 13, 2024
Maintains: Outperform
Price Target: $132 → $134
Current: $100.22
Upside: +33.71%
Nov 8, 2024
Reiterates: Outperform
Price Target: $46 → $48
Current: $27.66
Upside: +73.54%
Oct 30, 2024
Maintains: Market Perform
Price Target: $118 → $120
Current: $164.18
Upside: -26.91%
May 10, 2024
Maintains: Market Perform
Price Target: $7 → $6
Current: $1.37
Upside: +337.96%
Apr 26, 2024
Maintains: Outperform
Price Target: $80 → $82
Current: $201.76
Upside: -59.36%
Apr 25, 2023
Maintains: Outperform
Price Target: $20 → $19
Current: $5.52
Upside: +244.20%
Feb 3, 2022
Upgrades: Buy
Price Target: $170
Current: $318.65
Upside: -46.65%
Sep 9, 2020
Maintains: Buy
Price Target: $27 → $38
Current: $87.80
Upside: -56.72%
Mar 28, 2018
Maintains: Outperform
Price Target: $54 → $52
Current: $3.04
Upside: +1,610.53%